MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 8 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
PARP inhibitors attenuate chemotherapy‐induced painful neuropathy
Jill‐Desiree Brederson, Shailen K. Joshi, Kaitlin E. Browman, Joseph P. Mikusa, Chengmin Zhong, Donna M. Gauvin +5 more
2012· article· en· Journal of the Peripheral Nervous System· Medicine
machine prediction:candidate · noneconsensus · none
26
citations
afffundno abstractunlabeled
PARP enzyme de novo synthesis of protein-free poly(ADP-ribose)
Marie-France Langelier, Manija Mirhasan, Karine Gilbert, Aleksandr Sverzhinksy, Alexandra Fürtös, John M. Pascal
2024· article· en· Molecular Cell· Medicine
machine prediction:candidate · noneconsensus · none
24
citations
affno abstractunlabeled
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
R. Kristeleit, Ronnie Shapira‐Frommer, Ana Oaknin, Judith Balmañà, Isabelle Laure Ray-Coquard, Susan M. Domchek +11 more
2016· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
24
citations
afffundunlabeled
Advances in PARP Inhibitors for Prostate Cancer
Steven Tisseverasinghe, Boris Bahoric, Maurice Anidjar, Stephan Probst, Tamim Niazi
2023· review· en· Cancers· Medicine
machine prediction:candidate · noneconsensus · none
23
citations

How this was built: Screen · Findings · About